PTCT Q1 2024 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$210M-4.7% YoY

Gross Profit

$195M93.0% margin

Operating Income

-$45M-21.6% margin

Net Income

-$92M-43.6% margin

EPS (Diluted)

$-1.20

QoQ Revenue Growth

-31.6%

Cash Flow

Operating Cash Flow

$71M

Free Cash Flow

$6M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$2.7B

Stockholders' Equity

-$894M

Cash & Equivalents

$548M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$210M	$220M	-4.7%
Gross Profit	$195M	$206M	-5.3%
Operating Income	-$45M	-$118M	+61.4%
Net Income	-$92M	-$139M	+34.1%

Revenue Segments

Net product revenue

$178M99%

Manufacturing

$1M1%